The first possible limitation of this study is the heterogeneity of the studies regarding different ophthalmic diseases, including AMD, DME, PM, and RAP, which were assumed to have equivalent therapeutic responses for anti-VEGF treatment due to the active role of neovascularisation in their pathophysiology. Here, VEGFA is linked to age-related macular degeneration.